Pearce Michael Cooper 4

What Happened

• Pearce Michael Cooper, a director of Journey Medical Corp (DERM), received an award of 10,000 restricted stock units (RSUs) on June 25, 2026. The grant price is reported as $0.00, so no cash was paid by the insider; the total immediate value recorded in the filing is $0.
• This is an equity award (code A), not an open-market purchase or sale. RSUs represent a promise to issue shares if/when they vest and do not represent immediately tradable common stock.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-26 (one day after transaction).
• Amount: 10,000 RSUs granted at $0.00 per share (grant award).
• Vesting: Per the filing (F1), the 10,000 RSUs vest in full on June 25, 2027.
• Shares owned after transaction: not specified in the provided excerpt—see the full Form 4 for total beneficial ownership.
• Footnotes: F1 describes the June 25, 2026 grant and the one-year vest on June 25, 2027; F2 notes inclusion of RSUs that vest over various periods.
• Timeliness: Filing date is one day after the grant; Form 4s are typically due within two business days, so this appears timely.

Context

• RSU grants are common executive/director compensation and do not necessarily indicate immediate buying or selling sentiment. The shares will only be issued if and when the RSUs vest (here, one year later).
• Because this was an award (not a purchase or sale), there was no cash outlay or proceeds for the insider at grant.